Objective To characterize the prevalence and prognostic significance of major driver molecular alterations in adult midline diffuse gliomas (MLG).
Diffuse midline gliomas (MLG) are rare entities occurring predominantly in children and young adults. 1 Genomic studies in pediatric MLG showed that these tumors frequently harbor recurrent K27M missense mutations in H3F3A and HIST1H3B genes, which both encode variants of the histone H3 protein. [2] [3] [4] While HIST1H3B mutations are anatomically restricted to brainstem, 4, 5 H3F3A mutants have been reported in MLG of various locations. 2, [5] [6] [7] [8] In pediatric MLG, these mutations associate with more aggressive clinical phenotype and poorer prognosis. 6, 8, 9 Based on these observations, the WHO 2016 classification introduced "diffuse midline glioma, H3K27M-mutant" as a new grade IV entity, even in the absence of histopathologic markers of anaplasia. 10 In adults, fewer than 10% of diffuse gliomas arise in midline structures. 1, 11 Recent works suggested that they may differ from both pediatric MLG and adult supratentorial gliomas. As an illustration, although H3F3A mutations have been reported in adult MLG, 7, [12] [13] [14] [15] their prognostic significance in adults remains unclear. 12, 13 While less frequent, actionable 16, 17 IDH1 and FGFR1 hotspot mutations have been described in this population. 18, 19 Overall, the genomic landscape of adult MLG remains poorly understood. Indeed, the need for histologic confirmation in presence of a typical radiologic presentation is debated, because of the surgical risks and assumption of limited benefit on overall survival (OS). 20 We assumed that unravelling the genomic landscape of these tumors will enable better defining the prognostic value of molecular biomarkers in this disease and identify new therapeutic strategies. In this study, we report the clinical, histologic, and molecular characteristics of 116 adult patients with MLG, and assess the prevalence and prognostic significance of major driver molecular alterations.
Methods
Patients and tumor samples Patients (≥15 years) with diagnosis of MLG were retrospectively identified from our database (OncoNeuroTek, GH Pitié-Salpêtrière, Paris, 1996-2017) according to the following criteria: 1) tumor arising in midbrain location (thalamus, hypothalamus, pineal region, brainstem, cerebellum, or spinal cord), verified on neuroimaging at diagnosis; 2) histopathologic confirmation of diffuse glioma according to WHO 2016 classification; and 3) available follow-up data.
All tumor samples underwent histopathologic review (F.B. and K.M.) and, if required, additional diagnostic immunohistochemical stainings were performed. Radiologic analysis was performed by A.P. and J.S. and scored contrast enhancement (absent, mild/moderate, marked/ avid) and radiologic necrosis (none, <5%, 6%-33%, 34%-67%, >67% of the bulk), according to Visually Accessible Rembrandt Images (VASARI) criteria. 21 As a control, we used a set of hemispheric diffuse gliomas with available tumor DNA.
Standard protocol approvals, registrations, and patient consents All tumor samples and clinical data were collected with written informed consent in accordance with the tenets of the Declaration of Helsinki.
DNA extraction
DNA was extracted from formalin-fixed paraffin-embedded or frozen samples, as previously described.
Immunohistochemical analyses
Detection of IDH1 R132H mutant enzyme, Ki67, and ATRX nuclear expression were performed as previously described. 24, 25 In particular, the loss of nuclear ATRX expression was considered specific when tumor cell nuclei were unstained while the nuclei of non-neoplastic cells were ATRX-positive. Antibody antihistone H3.3 K27M mutant (ABE419; Millipore, Burlington, MA) was used at dilution 1/1,000. Samples were considered histone H3 K27M or IDH1 R132H mutated when immunohistochemistry was positive for the presence of the altered protein. 26, 27 Statistical analysis OS was defined as the time between diagnosis and death. Patients who were still alive at the last follow-up were censored for the analysis. Survival curves were calculated using the Kaplan-Meier method. Statistically significant differences between survival were assessed using the log-rank test. A log-rank test p value ≤0.05 (2-sided) was considered to be statistically significant. Cox model was used to evaluate the effect of quantitative variables on survival and for multivariate survival analysis. χ 2 and Fisher exact test were used to compare qualitative variables, with p < 0.05 considered as significant. Hierarchical clustering and multidimensional representations were used using the Ward method. The analyses were performed using R software packages.
Data availability
The complete individual data and supplementary material are available at doi: 10.5281/zenodo.1183373. Neurology.org/N Molecular characterization of adult MLG reveals the presence of recurrent hotspot mutations in FGFR1 The frequency and type of the main molecular alterations is detailed in figure 2 . As diagnosis was based on tumor biopsy in most of the patients and tissue availability was limited, molecular analyses were focused on the alterations hypothesized to be the most relevant to the disease. Comparative genomic hybridization array could be performed in 56 cases.
Results

Clinical and histologic features of adult MLG
Histone H3K27M mutations were found in 38/110 patients (34%) and were associated with a younger age at diagnosis (median 33 years vs 53 years, p = 6 × 10 −5 , figure e-1e, links.
lww.com/WNL/A510). Histone H3 mutations were mutually exclusive with IDH1, and inversely associated with TERTp mutation, p16/CDKN2A loss, and EGFR amplification (table e-1, links.lww.com/WNL/A511). H3K27M was found in all the locations but was associated with thalamic and spinal locations (table 1) .
IDH1 mutations were found in 6 patients (1 grade II, 4 grade III, 1 grade IV) out of 102: strikingly, all 6 IDH1 mutated tumors were located in brainstem (6/24 vs 0/78 for MLG not involving the brainstem; p = 7.5.10 −5 ). Only 1 out of the 5 IDH1 mutations identified by sequencing was IDH1 R132H; the other mutations were p.Arg132Gly (R132G) (2), p. Arg132Cys (R132C), andp.Arg132Leu (R132L), which contrasted with non-midline IDH1-mutant gliomas: we compared these results to the data from non-midline gliomas recorded in our tumor base (OncoNeuroTek) and found a difference in the pattern of IDH1 mutations between midline and non-midline gliomas (p = 0.0001): out of 2,234 IDH1 mutated supratentorial gliomas, 2,083 (93.2%) were R132H, 55 (2.5%) were R132G, 54 (2.4%) were R132C, 27 (1.2%) were R132S, and 15 (0.7%) were R132L. These data indicate that IDH-mutated brainstem gliomas differ from supratentorial IDH-mutated gliomas, and that immunohistochemistry anti-IDH1R132H is not the valid method for IDH screening in these tumors.
Fifty-nine patients were found IDH wild-type and K27 wildtype: this group-IDHwt-K27wt-of MLG had more frequent TERTp mutation (24/48, p < 1 × 10
), CDKN2A deletion (7/24, p = 0.028), and EGFR amplification (5/24, p = 0.016) (figure 2). No patient had BRAF V600 mutation (0/69).
Recurrent FGFR1 mutations affecting 2 hotspots were identified in 18% of patients (13/73): p.Asn546Lys (9), p. Asn546Asp (2), and p.Lys656Glu (2) with diverse locations: 7/37 thalamus (19%), 2/12 brainstem (17%), 2/13 cerebellar (15%), and 1/3 spinal cord (33%) (p = 0.9), in both K27M MLG (6/23) and K27wt MLG (6/45), p = 0.3; and 6/41 IDH wild-type vs 0/4 IDH mutated, p = 1 (figure 2). In order to investigate whether FGFR1 mutations were specific to midline located diffuse gliomas, we sequenced from our OncoNeuroTek tumor bank 479 DNA samples extracted from hemispheric gliomas (170 GBM, 151 grade III, 157 grade II, of which 197 were IDH mutated, 212 IDH wild-type, and 70 undetermined) for the presence of FGFR1 mutations: we found only one mutation in a patient with an IDH wild-type GBM involving the corpus callosum, suggesting that FGFR1 mutations are restricted to midline diffuse gliomas (13/73 vs 1/479; p = 1.2.10
−10
). Our data were further confirmed by public data (cbioportal.org): out of 1,722 patients with diffuse gliomas, only 2 patients had FGFR1 activating mutation (13/73 vs 2/1,722; p = 10 −16 ): 1 GBM with K656E Figure 2 Age, tumor location, tumor grade, and molecular alterations of 116 patients with midline gliomas mutation but no clinical information on location 28 and 1 1p/ 19q-codeleted IDH1 mutantfrontal oligodendroglioma with N546K mutation. 29 We then performed a hierarchical clustering on the clinical, histologic, radiologic, and molecular alterations (figure e-2, links. lww.com/WNL/A510). This table shows that IDH1 mutations cluster with the brainstem location, and FGFR1 mutations cluster with extinction of ATRX expression (p = 0.02), while CDKN2A loss clusters with EGFR (p = 0.0004) and TERTp (p = 0.01) mutations. Grade, radiologic necrosis, and contrast enhancement clustered together. All the variables are reported in a correlation matrix (figure 3) showing the positive (blue) and negative (red) associations. FGFR1 mutations tended to be associated with younger age (p = 0.06), as ATRX loss (p = 0.05), while TERTp mutation (p = 0.1) and EGFR amplification (p = 0.05) tended to be associated with older age. 
Survival analysis
MGMT methylation, % (n) figure  e-5a) . None of the IDH1 mutant brainstem MLG showed contrast enhancement (0/5) vs 6/10 in IDH1 wild-type MLG (p < 0.05) ( figure e-5, b-d) .
IDH wild-type-K27 wild-type patients showed the worst outcome ( figure 4C ). This group had frequent TERTp mutation, CDKN2A deletion, and EGFR amplification, all associated with shorter survival ( (table 3) .
Discussion
This retrospective study shows that adult MLG constitute a heterogeneous group with mostly high-grade neoplasms and clinical and histomolecular characteristics differing from both pediatric MLG and adult supratentorial high-grade gliomas. We identified 2 main subgroups based on the presence of histone H3 or IDH1 mutations, and identified hotspot FGFR1 mutations as the main potential target in this population.
The most prominent molecular subgroup consisted of histone H3 mutant MLG, in line with previous studies showing a strong association between histone H3 mutations and gliomagenesis of midline tumors. [2] [3] [4] [5] [6] 8, [12] [13] [14] [15] 18, 33 However, we observed a lower prevalence of histone H3 mutations compared to pediatric highgrade thalamic and brainstem gliomas (70%-80%).
2,4-6 In addition, clinical and molecular characteristics of patients from our cohort with histone H3 mutant MLG differed from pediatric patients. 2, 4, 6, 33 First, although histone H3 mutations were associated with younger age at diagnosis (median 33 years vs 53 years, p = 6 × 10
), we found H3 mutation in patients over 60 years, indicating that screening for histone H3 mutants should be considered in all MLG cases, regardless of age. Moreover, in contrast to pediatric gliomas, we found that histone H3 mutations were not associated with a worse prognosis compared to the other IDH wild-type gliomas 12, 14 : in the largest group, i.e., the thalamic MLG, H3 mutations were even associated with better outcome. While H3 G34 and to a lesser extent K27 mutations have been associated with alternative lengthening of telomeres in pediatric tumors, as reflected by frequent ATRX inactivation, 3, 6, 8, 12, 34 we also found H3 mutation associated with TERTp mutation in 5 patients. Interestingly, either ATRX loss or TERTp mutation tended to be associated with poorer outcome in the subset of H3 mutated gliomas (OS 9.8 vs 24.2 months; p = 0.08; data not shown).
The other main driver of alteration is IDH mutation, which occurs specifically in brainstem (6/24 vs 0/78 in other midline localizations). The majority of IDH1 mutations in this cohort were non-R132H, indicating that the widely used anti-R132H immunohistochemistry is not appropriate in brainstem gliomas and has probably underestimated the proportion of IDH1-mutant tumors. 35 Systematic IDH1 sequencing should be performed whenever feasible in brainstem gliomas. Indeed, as observed in hemispheric gliomas, IDH1 mutation is associated with better outcome (OS 54.1 vs 15.9 months in our cohort), and may in part explain why adults with brainstem gliomas have better survival than children. 19, 35, 36 In addition to its prognostic value, the recognition of IDH1 mutations may open therapeutic opportunities, as inhibitors of IDH1-mutant enzymes have demonstrated antitumor potential and entered clinical trials for patients with IDH1 mutations. 37 In addition to IDH1 mutation, we identified other potentially targetable hotspot mutations affecting N546 and K656 residues of FGFR1 in 19% of our patients. In contrast to IDH1 mutation, FGFR1 mutations were not associated with any specific location or any molecular subgroup. Somatic FGFR1 N546 and K656 mutations were previously reported in several other cancer types, 36, 38 comprising a wide range of CNS tumors: rosette-forming glioneuronal tumors, 39 dysembryoplastic neuroepithelial tumors, 40 pilocytic astrocytomas, 41, 42 diffuse leptomeningeal tumor with glial and neuronal markers, 43 and pediatric thalamic gliomas. 3, 18, 19, 43 These studies analyzed isolated cases or small cohorts, which made difficult the assessment of the incidence of FGFR1 mutations in this population. FGFR1 N546 and K656 mutants lead to constitutive activation of FGFR1 tyrosine kinase and downstream RAS-MAPK signaling, contributing to transformation, 44 and can be targeted by a number of oral highly specific FGFR inhibitors, currently under clinical evaluation, 16 such as BGJ398, AZD4547, JNJ-42756493, and TAS-120 (a novel irreversible FGFR inhibitor that demonstrated potent activity against N546K mutants), 45 opening new therapeutic opportunities in this population. BRAF V600E is another actionable target, which has been rarely associated with H3K27M in pediatric gangliogliomas and diffuse midline gliomas. 7, [46] [47] [48] However, we did not find any BRAF V600 mutation in all the 68 sequenced patients.
Our study was restricted by the scarcity of available tumor material limiting both histopathologic and genomic analyses. Therefore, our genomic analyses, when possible, were restricted to a panel of selected molecular alterations, while several samples were exhausted at the time of this retrospective analysis. However, the majority of the patients could be assessed for TERT promoter status, which was not covered by previous whole-exome sequencing studies or was technically limited in whole-genome sequencing studies by the very low coverage due to the high GC content of the TERT promoter region. 4, 19 As observed in adult supratentorial glioblastomas, TERTp mutation, which affected 37% of our patients, was associated with older age, grade IV, poor survival, EGFR amplifications, loss of chromosome 10, and deletion of CDKN2A. Survival of these patients was particularly poor (OS 9.1 months vs 24.2 months for patients without TERTp mutations), even compared to adult patients with hemispheric glioblastomas followed in our institution (OS 13.5 months 49 ), which may be related to the inability to resect these tumors. TERT promoter appears therefore a prognosticator biomarker of poor survival in patients with adult MLG.
Our findings reinforce the need for histologic confirmation and molecular analyses in adult patients with MLG, given the significant heterogeneity among midline tumors and the presence of recurrent potentially targetable molecular alterations in these often-fatal diseases. While IDH1 and TERT promoter mutations may assist treatment stratification in adult patients with MLG, we show here that histone H3 mutations do not confer worse prognosis in adult patients with MLG. Our finding of frequent and potentially targetable FGFR1 mutations has important clinical implications in the current context of anti-FGFR trials, and further reinforces the need for molecular analyses. In this population characterized by a risk for biopsies, the development of liquid biopsy allowing a noninvasive assessment of these few mutational hotspots therefore would be particularly relevant. 
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